Navigation Links
Gerson Lehrman Group Extends Partnership With BIO to Provide Scientific Expertise for the First Annual BIO National Venture Conference

Conference will be held April 22-23 at the Hyatt Regency Cambridge,


NEW YORK, April 8, 2008 /PRNewswire/ -- Gerson Lehrman Group, the world's leading marketplace for expertise, and the Biotechnology Industry Organization (BIO) announced an extension of their partnership with this latest initiative focused on providing the venture investment community, registered to attend the BIO National Venture Conference, with scientific expertise on the most promising early-stage biotechnology innovations.

GLG Council Members, including nationally recognized clinicians and researchers, will be speaking during therapeutic workshops at the inaugural BIO National Venture Conference, along with pharmaceutical and biotechnology industry senior executives to discuss innovative treatment advances in the fields of new antibiotics, RNA-based therapies, and stem cell/regenerative medicine.

"As with our efforts during the prestigious BIO CEO and Investor Conference in February 2008, we are very pleased to join with the Biotechnology Industry Organization to program the only truly independent conference series for healthcare industry decision makers, where the sole focus is premier education," said Alexander Saint-Amand, Chief Executive Officer of Gerson Lehrman Group. "By partnering with BIO and their highly respected investor conference series, Gerson Lehrman Group can make available its unparalleled network of healthcare experts to help educate decision makers in every industry by connecting them to the academic and industry leaders driving innovation and productivity in our global economy."

Through this partnership, BIO will tap into Gerson Lehrman Group's network of more than 175,000 experts from around the world. The panel speakers will be specifically identified to focus on some of the most interesting and novel development areas within the biotechnology industry: antibiotics, RNA-based therapies, and stem cell/regenerative medicine. These workshop topics were identified in a thorough vetting process by BIO in collaboration with the venture capital community.

"The depth and breadth of expertise available through Gerson Lehrman Group is a great fit for BIO's continuing efforts to provide cutting-edge education to our conference registrants, who themselves are some of the most informed healthcare industry experts," said Jim Greenwood, President and Chief Executive Officer of BIO. "Workshops selected for the BIO National Venture Conference are representative of the most compelling topics for biotechnology venture start-ups today, and focus on educating investors and industry on the latest areas of pipeline innovation, as well as strategies for capitalization and supporting product development objectives."

The first annual BIO National Venture Conference will feature select early-stage private biotechnology companies from across the U.S. The goal of this new national meeting is to bring together an elite group of healthcare venture partners for a concentrated one and a half day event. Workshops and plenary sessions on trends in the industry will also be held, with special focus on key success factors for early-stage companies, market trends, and financing. In addition, there will be formal and informal networking opportunities with industry CEOs and venture capital leaders.

To see the latest updates to 2008 programming and speakers for BIO National Venture Conference, please visit

About Gerson Lehrman Group

Gerson Lehrman Group provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. Gerson Lehrman Group's unparalleled network of the world's leading expert consultants, known as the GLG Councils, includes more than 175,000 subject matter experts who educate and provide insight to decision makers through a wide range of consulting methods, including telephone consultations, expert surveys, and seminars. Gerson Lehrman Group has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about Gerson Lehrman Group, please visit

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Gerson Lehrman Group Contact:

Margaret M. Molloy


Biotechnology Industry Organization Contact:

John Craighead, Ph.D.


SOURCE Gerson Lehrman Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
2. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
3. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
4. MiMedx Group Announces Post-split Name Change
5. Photonic Products Group, Inc. Reports Record Financial Results for FY 2007
6. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
7. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
8. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
9. BioAnalytics Group CEO, Senior Scientist to Present at Tucson Symposium March 12-13
10. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
11. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
Post Your Comments:
(Date:10/12/2015)... This report covers the global cell expansion ... applications, end-user markets and geographic segmentation. Forecasts are provided ... cell expansion market generated revenue of roughly $8.5 billion ... $9.7 billion in 2015 and $22.0 billion by 2020, ... from 2015 to 2020. This report provides: ...
(Date:10/12/2015)... Oct. 12, 2015  Patara Pharma, a clinical-stage ... inflammatory diseases and conditions, today announced the closing ... financing. Concurrent with the close of its sale ... Loan and Security Agreement with Silicon Valley Bank ... million. Patara will use the funds from the ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty biopharmaceutical company focused ... safely and chronically be administered as an eye drop, announced today it has been ... Clinic and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, ...
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... 29, 2015 News facts: ... also saving energy , Minimized design shrinks PC ... Active Mode and embedded Fujitsu PalmSecure authentication enable enterprises ... Fujitsu today shows that good things come in small ... to its enterprise desktop and mobile portfolio. Featuring workplace ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
Breaking Biology News(10 mins):